Recent briefings covering the period to 17 June 2026 contained no material Eli Lilly-specific disclosures [Brief - 2026-06-17]. Macro commentary across multiple briefing dates centred on geopolitical escalation in the Middle East, including a confirmed Israeli strike on Iran's Mahshahr petrochemical complex on 8 June 2026 that drove Brent crude to $94 per barrel during the European session — the first confirmed energy-sector attack since an April ceasefire [Brief - 2026-06-08]. Separately, Iranian military action involving drone and missile strikes on Kuwait International Airport was reported overnight on 3 June 2026 [Brief - 2026-06-03]. No LLY-specific operational or clinical disclosures appeared in the briefing record during this window.
Eli Lilly's trailing twelve-month revenue as of 31 March 2026 stood at $72.25 billion, representing year-over-year growth of 55.5%. Net income for the same period was $25.28 billion, producing a net margin of approximately 35.0%. EPS grew 169.9% year-over-year. The company reported cash of $5.28 billion against total debt of $43.37 billion as of the same date. The trailing P/E ratio stood at 39.69 [SEC 10-Q - LLY - 2026-03-31].
Five insider transactions were recorded in June 2026, with net direction indicating selling activity totalling approximately $2.88 million in net value [SEC Form 4 - LLY - 2026-06]. Among institutional holders, Citadel reduced its position by 29% and Millennium reduced its position by 6.5%, while AQR Capital added 69% to its existing position and ARK Invest opened a new position in LLY during the same reporting period [SEC 13F - Citadel - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - ARK Invest - Q1 2026]. These material institutional position changes constituted the primary trigger for this report.
The 10-year US Treasury yield stood at 4.50% and the 2-year yield at 4.16% as of the report generation date, with the yield curve in a normal configuration [FRED DGS10] [FRED DGS2]. The spread of 34 basis points between the 2-year and 10-year tenors reflects the prevailing rate environment against which equity valuations, including LLY's reported P/E of 39.69, are observed.